Last updated: February 13, 2026
What Is the Market Status of NDC: 69230-0304?
NDC 69230-0304 corresponds to Furosemide Oral Solution 10 mg/5 mL, a diuretic used primarily to treat edema and hypertension. This formulation is a liquid version of furosemide, typically prescribed for patients with difficulty swallowing tablets or requiring precise dosing adjustments.
The drug market for furosemide in its oral solution form is relatively niche, representing a small segment within the larger diuretic class. The majority of furosemide prescriptions are for tablets, which dominate the market due to convenience and cost advantages.
How Competitive Is the Market for Furosemide Oral Solution?
Market Players
- Baxter Healthcare produces a generic furosemide oral solution.
- Several generic companies supply similar formulations, with no current FDA-approved branded versions.
- No recent high-profile licensing agreements or partnerships dominate the liquid segment, signaling limited market concentration.
Market Size
- The overall U.S. diuretics market was valued at approximately USD 2.2 billion in 2022 ([1]).
- Furosemide accounts for over 60% of diuretic prescriptions ([2]).
- Liquid formulations are estimated to constitute approximately 10-15% of total furosemide prescriptions, translating into an estimated USD 132-330 million segment.
- Growth in this segment depends on pediatric and elderly populations and the emergence of new indications.
Prescription Trends
- A slight decline in oral solution prescriptions is observed, correlating with the increasing preference for tablet formulations.
- Pediatric and intensive care units continue to rely on liquid forms, maintaining niche demand.
Price Projections and Revenue Potential
Current Pricing Landscape
- Generic furosemide oral solution 10 mg/5 mL sells for roughly USD 3.50 to USD 5.00 per 100 mL (approximate wholesale acquisition cost).
- Price variation exists based on supplier, packaging, and regional factors.
- Brandless generics have minimal price differences but offer substitution flexibility.
Price Trends
- No significant upward price trend is observed over the last five years.
- Increased competition among generic suppliers keeps prices relatively stable.
- Moderate price erosion may occur if new generic entrants enter the space.
Revenue Forecasts
- For a manufacturer with a new or existing approval, captured market share could generate USD 2-10 million annually at niche levels.
- A 10-15% market share within the liquid furosemide space could translate into USD 20-50 million in sales if production scaleings are optimized.
Regulatory and Market Entry Considerations
Regulatory Pathways
- FDA approval for generic liquid furosemide requires demonstrating bioequivalence to the reference product.
- Orphan drug status is unlikely due to broad indication, but orphan designation could benefit specific pediatric markets.
Market Entry Barriers
- Establishing manufacturing quality consistent with current standards.
- Accelerated market penetration demands competitive pricing.
- Hospitals and clinics prefer existing suppliers unless superior features justify switching.
Competitive Positioning and Differentiation Strategies
- Developing formulations with improved stability or palatability.
- Packaging innovations for ease of administration.
- Emphasizing cost-effectiveness and reliable supply chains to gain market share.
Key Takeaways
- The market for NDC 69230-0304 (furosemide oral solution 10 mg/5 mL) remains niche, with stable but slow-growing demand driven mainly by pediatric and critical care sectors.
- Price points stay within a narrow range, with minimal growth trends.
- Entry barriers are manageable, with brand and generic competitors operating in a highly commoditized segment.
- Revenue potential depends on capturing a significant share of a USD 132-330 million segment.
FAQs
What approvals are needed to market this drug?
FDA approval requires demonstrating bioequivalence and manufacturing compliance under ANDA (Abbreviated New Drug Application) pathways.
Is there demand for liquid formulations of furosemide?
Yes, especially in pediatric, geriatric, and critical care settings where tablets are unsuitable.
Who are the primary competitors?
Generic manufacturers like Baxter and several other regional suppliers with established versions.
What is the outlook for price changes?
Prices are stable; significant increases are unlikely unless supply chain disruptions occur or novel features are introduced.
Are there opportunities in markets outside the U.S.?
Emerging markets may have higher demand, but regulatory and pricing differences could impact profitability.
Sources
[1] Grand View Research, "Diuretics Market Size & Trends," 2022.
[2] IQVIA Data, "Prescription Trends for Diuretics," 2022.
[3] FDA, "Approved Drugs and Labeling," 2023.
